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Indiscriminate use of LVRS should be avoided,
and appropriate patient selection by rigorous as-
sessment is mandatory [10, 11]. LVRS should be
considered a palliative procedure to be offered
only to a minority of patients with severe emphy-
sema [11].
Assessment for LVRS is based on (a) general,
(b) functional and (c) imaging features. These cri-
teria, currently applied in most institutions, are
summarized in table 1. Clinical criteria include
age, which is arbitrarily cut off at 75 years, smok-
ing cessation and absence of general or local con-
traindications for surgery. Functional criteria play
an essential role in patient selection. Relevant re-
sults in this respect recently emerged from a pre-
liminary report of the National Emphysema
Treatment Trial: a significantly impaired outcome
with high postoperative mortality and little func-
tional benefit in survivors has been observed in pa-
tients with DLCO <20% in combination with
FEV1 <20% predicted [12]. Morphological crite-
ria, mainly established by high resolution CT scan
and ventilation- perfusion lung scintigram (fig. 1),
are useful tools in determining a heterogeneous
pattern of emphysema and identifying target areas
of non-functional lung parenchyma for resection
[13, 14]. Imaging features are considered impor-
tant predictors of postoperative functional out-
come [10, 11, 15]. In heterogeneous emphysema
with upper lobe predominance LVRS has a better
and longer-lasting effect than in homogeneous
emphysema [15]. This was recently emphasised in
a retrospective analysis by Kotloff et al., who de-
Lung volume reduction surgery (LVRS), first
described by Brantigan in 1957, has recently been
reintroduced and refined as a treatment option in
the management of severe disabling pulmonary
emphysema [1, 2]. This surgical approach to em-
physematous lung disease allows resection of the
most impaired and non-functional lung tissue,
with improvement of respiration mechanics and
enhancement of the lung’s elastic recoil and com-
pliance [3, 4]. The method has shown promising
short-term results with substantial improvement
of dyspnoea, exercise tolerance, quality of life and
pulmonary function in carefully selected patients;
this has been observed in some recent controlled
trials comparing LVRS with medical treatment
[5–9]. However, despite widespread use of the pro-
cedure and the rapid progress of the technique,
some aspects are still controversial or incompletely
elucidated. The aim of this article is to summarise
some of the recent data about patient selection cri-
teria and surgical technique, with particular em-
phasis on the role of LVRS in lung cancer surgery
and on the unilateral VATS approach. 
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Selection criteria for LVRS
Clinical criteria
• Age <75 years
• Smoking cessation
• Absence of severe ischemic heart disease
• Absence of malignancy or poor medical condition
• Absence of severe nutritional disturbancies
• Absence of local contraindications for surgery 
(previous operation, pleurodesis, major thoracic deformity)
Functional criteria
• FEV1 20–35% predicted
• DLCO >20% predicted
• Hyperinflation with increased RV/TLC and 
RV >200% predicted
• Mean pulmonary artery pressure <35 mmHg
• PaCO2 <55 mmHg
Imaging criteria
• Heterogeneous pattern of emphysema on high resolution CT 
Scan and on ventilation perfusion scintigraphy
Table 1
Selection criteria 
for LVRS.
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fined the apical perfusion fraction as the percent-
age of total lung perfusion to the apical third of
both lungs [16]. A significantly better postopera-
tive functional improvement was observed in pa-
tients with marked apical hypoperfusion and an
apical perfusion fraction of <10%.
To better define the lung areas and the amount
of tissue to be resected, the preoperative morpho-
logical criteria need further refinement. This may
be accomplished by assessing regional lung func-
tion, possibly obtained by superposition of venti-
lation-perfusion scintigram and high-resolution
CT scan. 
Figure 1
Lung perfusion
scintigraphy showing
heterogeneous
pattern of disease
with upper lobe
predominance.
The incidence of solitary pulmonary nodules in emphysema patients
Among the clinical criteria, poor medical con-
dition and non-thoracic malignancy have gener-
ally been considered contraindications for surgery
[11]. In addition, candidates for LVRS are at high
risk of developing lung cancer, and preoperative
assessment may lead to the incidental discovery of
pulmonary nodules, as shown in figure 2 [17–19].
On preoperative imaging or histological analysis of
the surgical specimen Hazelrigg and co-workers
identified at least one pulmonary nodule in 39.5%
of 281 patients undergoing LVRS [17]. 78 nodules
were resected, 17 were malignant and 13 cases of
non-small-cell lung cancer (NSCLC) were ob-
served. 
McKenna et al observed a nodule in 51 (16%)
of 325 patients evaluated for LVRS and 11
NSCLC were identified [18]. Only 3 patients were
treated by formal lobectomy and wedge resections
were carried out in the remaining 8 cases.
Pigula described 10 similar cases undergoing nod-
ule resection in conjunction with LVRS [19].
Figure 2
Left lower lobe 
solitary pulmonary
nodule incidentally
discovered during
LVRS assessement.
The incidence of lung cancer in emphysema patients
Non-small-cell lung cancer (NSCLC) is
nowadays treated by anatomical lung resection
(lobectomy or pneumonectomy), and procedures
of lesser extent such as wedge or segmental resec-
tions carry a significantly higher risk of local re-
currence [20]. The simultaneous presence of em-
physematous lung disease and cancer is a not in-
frequent and vexing clinical problem. Anatomical
lung resection would normally be considered a
prohibitively high risk for these patients because
of poor underlying pulmonary function. However,
traditional operability criteria for lung cancer have
somewhat changed with growing experience of
LVRS. It has been shown that patients with
NSCLC and severe emphysema considered inop-
erable because of poor lung function may not only
undergo lobectomy safely but may even have in-
creased pulmonary function after resection. This
is primarily due to an effect of LVRS related to tu-
mour resection. LVRS criteria may therefore be
extended and applied to selected patients present-
ing with lung cancer associated with severe em-
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the neoplasm is located in the target area for LVRS
[18, 19, 22]. In our experience 10 patients have un-
dergone surgery in this setting. In 7 cases the neo-
plasm was located in target areas for LVRS and
these patients underwent lobectomy (fig. 3). Im-
proved lung function was seen after cancer resec-
tion combined with LVRS. In the remaining 3
cases the lesion was in a part of the lung not con-
sidered for LVRS and the patients underwent seg-
mental resection combined with upper lobe LVRS
(fig. 4). A favourable postoperative outcome was
observed in all the cases. Nevertheless, further
studies are required to determine the value of this
concept in terms of long-term functional outcome
and cancer-related survival.
Figure 3
Right upper lobe
NSCLC in a patient
with severe heteroge-
neous emphysema
with upper lobe pre-
dominance, as seen
on chest X-ray 
(fig. 3a) and on pre-
operative perfusion
scintigraphy (fig. 3b).
Preoperative and
postoperative FEV1
and RV were 1,60 L
(52%), 4,87 L (222%)
and 2,47 L (80,5%),
2,38 L (108%) respec-
tively.
physema. However, this is only possible in situa-
tions where the tumour is located within the tar-
get area for LVRS, as highlighted by Edwards et
al., who introduced the principle of “lobar volume
reduction surgery” [21]. The feasibility of lobec-
tomy was demonstrated in 29 emphysematous pa-
tients; two groups were considered on the basis of
postoperative predicted FEV1 (>40% and <40%
respectively). In the group with the most severe
functional impairment the measured post- opera-
tive FEV1 was significantly higher than predicted,
a fact which paralleled the postoperative functional
improvement observed in this group of patients as
compared to the preoperative status [21]. Other
reports have also shown a subjective and objective
improvement in emphysema patients undergoing
lobectomy for lung cancer if the cancer is within
the target areas of anticipated LVRS [22–24].
There is increasing evidence that selected patients
harbouring concomitant emphysema and pul-
monary malignancy can undergo simultaneous
LVRS and cancer surgery [18, 21, 22], but only ifa
b
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First performed by sternotomy, LVRS was
then accessed by VATS, which is now considered
as the technique of choice. Whether LVRS should
be performed as a unilateral or bilateral simulta-
neous procedure is still controverted. To date no
randomised prospective study has compared uni-
lateral versus bilateral LVRS. Several studies have
shown a better clinical and functional outcome
after the bilateral procedure than after the unilat-
eral approach [25–27]. McKenna et al. reported a
better functional outcome after bilateral thoraco-
scopic LVRS and noticed lower 1-year mortality
compared with unilateral LVRS [25]. These results
contrast with those of Kotloff et al. [26], who re-
ported an increase in hospital mortality and post-
operative respiratory failure in patients treated by
simultaneous bilateral LVRS. Similarly, Serna and
co-workers described better results after bilateral
LVRS with significantly higher 2-year survival
[27]. Naunheim et al. found no difference in sur-
vival between bilateral and unilateral LVRS [28].
Our experience with a systematic unilateral VATS
approach since 1996 has shown no mortality, tra-
cheostomy or prolonged intensive care unit stay
after LVRS. Significant clinical and functional
benefit was noticed in 28 patients during a follow-
up which lasted at least 2 years [29]. Only 2 pa-
tients, both with alpha-1-antitrypsin deficiency,
underwent contralateral surgery during the obser-
vation period. LVRS should be considered a purely
palliative procedure and, in consequence, the least
aggressive approach should be chosen that will re-
sult in an acceptable quality of life, which need not
necessarily be reflected in pulmonary function
measurements. In addition, after the unilateral
procedure LVRS can be repeated on the con-
tralateral side if required; however, the published
results after staged bilateral LVRS are scant and
controversial. Pompeo et al. reported a better clin-
ical outcome after staged bilateral than after si-
multaneous bilateral LVRS [30]. Although a si-
multaneous bilateral approach may lead to better
immediate functional results than a unilateral pro-
cedure, the subsequent decline and loss of pul-
monary function during the postoperative period
is also more pronounced after bilateral than uni-
lateral procedures. An annual decline of 260 ml vs
100 ml respectively has been reported [31]. This
aspect needs to be investigated in a properly con-
ducted prospective study investigating the value of
LVRS in emphysematous patients, patient selec-
tion and the best surgical approach.
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Surgical technique
Figure 4
Chest X-ray showing
stage I left lower lobe
NSCLC in a patient
with severe hetero-
geneous emphysema
submitted to apical
segmentectomy of
the left lower lobe.
Preoperative and
postoperative FEV1
and RV were 0.82 L
(34%), 2,74 L (150%)
and 0,84 L (34%),
3,28 L (185%) respec-
tively.
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